Advanced prostate cancer—a case for adjuvant differentiation therapy

@article{Rane2012AdvancedPC,
  title={Advanced prostate cancer—a case for adjuvant differentiation therapy},
  author={Jayant K. Rane and Davide Pellacani and Norman J. Maitland},
  journal={Nature Reviews Urology},
  year={2012},
  volume={9},
  pages={595-602}
}
The development of novel therapies such as abiraterone acetate and sipuleucel-T has improved the outlook for patients with advanced-stage and castration-resistant prostate cancer. However, the beneficial effects of these drugs are only measured in months. Moreover, the National Institute for Health and Clinical Excellence in the UK had ruled that the use of abiraterone acetate was not cost-effective before cost revision by the manufacturers. The FDA statement asserting that the use of 5… Expand
Targeting the Prostate Stem Cell for Chemoprevention
TLDR
This chapter will discuss the use of chemoprevention to target cancer stem cells and how these approaches can be applied to prostate cancer. Expand
Molecular pathways and targets in prostate cancer
TLDR
This review summarizes the current understanding of the molecular pathways involved in localized and metastatic prostate cancer, with an emphasis on the clinical implications of the new knowledge. Expand
Cancer Stem Cells Provide New Insights into the Therapeutic Responses of Human Prostate Cancer
TLDR
The role of cancer stem cells in tumour relapse as well as the potential they provide to develop novel treatment strategies are described and three strategies to target both cancer stem Cells and bulk tumour cells are proposed. Expand
Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium
TLDR
The known and proposed roles of the ETS family of transcription factors in prostate epithelial cell differentiation and regulation of the CSC phenotype will be discussed, as well as how they might be targeted for therapy. Expand
Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and review of the literature
TLDR
The case of a 73-year-old man, affected by bone metastatic CRPC, early treated with Radium-223 with a complete response and to the knowledge, he is the unique described case of the reversion of resistance to castration. Expand
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations
TLDR
Analysis of clinical samples and patient-derived prostate epithelial cultures revealed Cancerous inhibitor of protein phosphatase 2A (CIP2A) as one such target, highlighting its potential therapeutic significance in the most clinically challenging prostate pathology: castration-resistant prostate cancer. Expand
Therapy escape mechanisms in the malignant prostate.
TLDR
The current knowledge of molecular mechanisms underlying therapy resistance in prostate cancer, arranged into the concepts of target modification, bypass signalling, histologic transformation, cancer stem cells and miscellaneous mechanisms, is summarised. Expand
Loss of SLCO1B3 drives taxane resistance in prostate cancer
TLDR
The SLCO1B3 determines intracellular concentrations of docetaxel and cabazitaxe and consequently influences taxane efficacy and may drive taxane resistance in prostate cancer. Expand
Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer
TLDR
Major biomarkers for prostate cancer stem cells are summarized, as well as their functional mechanisms and potential application in clinical diagnosis and treatment of patients. Expand
Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review
TLDR
The cost-effectiveness of treatments of CRPC strongly depended on the willingness to pay per quality-adjusted life year gained/life-year saved throughout all included costs-effectivity analyses and model-based economic evaluations. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 129 REFERENCES
The changing therapeutic landscape of castration-resistant prostate cancer
TLDR
A treatment pathway for patients with CRPC is proposed and strategies to optimize the use of these agents are considered, including the incorporation of predictive and intermediate end point biomarkers, such as circulating tumor cells. Expand
New therapies for castration-resistant prostate cancer: efficacy and safety.
TLDR
The efficacy and safety of approved agents, promising therapies that have proceeded to phase 3 evaluation, and those that have enhanced the understanding of the biology of CRPC are focused on. Expand
Abiraterone in Prostate Cancer: A New Angle to an Old Problem
TLDR
Abiraterone's efficacy shows the importance of androgen signaling in patients with castrate-resistant metastatic disease, with additional confirmation from recent studies of other novel agents such as MDV3100, an androgen receptor signaling inhibitor. Expand
Abiraterone and increased survival in metastatic prostate cancer.
TLDR
The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. Expand
Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.
TLDR
Liarozole is superior to CPA in terms of PSA response, PSA progression, and survival, and is capable of maintaining patients' quality of life. Expand
Gamma‐tocotrienol as an effective agent in targeting prostate cancer stem cell‐like population
TLDR
It is demonstrated for the first time that γ‐T3 can downregulate the expression of prostate CSC markers (CD133/CD44) in androgen‐independent prostate cancer cell lines (PC‐3 and DU145), as evident from Western blotting analysis. Expand
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.
  • G. Attard, A. Reid, +16 authors J. D. de Bono
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
YP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven. Expand
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
  • Y. Ning, J. Gulley, +14 authors W. Dahut
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
The addition of bevacizumab and thalidomide to docetaxel is a highly active combination with manageable toxicities, and the estimated median survival is encouraging, given the generally poor prognosis of this patient population. Expand
Prospective identification of tumorigenic prostate cancer stem cells.
TLDR
The identification and characterization of a cancer stem cell population from human prostate tumors, which possess a significant capacity for self-renewal and are able to regenerate the phenotypically mixed populations of nonclonogenic cells, which express differentiated cell products. Expand
The effects of telomerase inhibition on prostate tumor‐initiating cells
TLDR
It is found that prostate TICs have significant telomerase activity which is inhibited by imetelstat sodium (GRN163L), a new telomersase antagonist that is currently in Phase I/II clinical trials for several hematological and solid tumor malignancies. Expand
...
1
2
3
4
5
...